Arvinas Inc. is looking to raise $400 million via an offering of stocks.
The New Haven, Conn.-based biopharmaceutical company priced an offering of 5,714,286 common shares at $70 each to raise the funds. The offering's underwriters — Goldman Sachs & Co. LLC, Piper Sandler & Co., Cantor Fitzgerald & Co. and BMO Capital Markets — have an option to buy up to an additional 857,142 common shares from the company.
The offering is expected to close by Dec. 18.
Arvinas develops therapies to degrade disease-causing proteins. Its lead products include ARV-110 which is being developed for treating a type of prostate cancer and ARV-471 which is being developed for treating a type of breast cancer.